10:18 AM EDT, 09/23/2024 (MT Newswires) -- BioAtla ( BCAB ) and Context Therapeutics ( CNTX ) said Monday they have entered into an agreement granting Context an exclusive worldwide license to develop, produce and market BA3362, BioAtla's ( BCAB ) Nectin-4 x CD3 T-cell engager.

Under the terms, BioAtla ( BCAB ) will receive $15 million in upfront and near-term milestones, and is eligible to receive up to $133.5 million in total payments along with tiered royalties on net sales, the companies said.

Context will assume and fund all development and commercialization activities, the companies said.

Price: 1.70, Change: -0.02, Percent Change: -1.16